Views & Analysis | Perspectives on pharma industry issues

Digital

Prescribed, but never filled: Why patient access is broken

Patient access is no longer just an administrative backroom function; it is a core determinant of health outcomes.

Market Access

pharmaphorum podcast Episode 270, Alice Valder Curran, Hogan Lovells

Policy in Focus: What’s new with CMS drug price negotiation,...

Hogan Lovells partner Alice Valder Curran returned to elucidate some of the finer points of the latest communication from CMS.

R&D

The reasoning problem

In R&D, decisions that matter most rarely happen during the documented steps; they happen in the pauses between them.

Digital

Patient access will not improve without better digital found...

Digital health cannot succeed without infrastructure that supports it at every level.

Digital

The SPR must be built for the health system to come

The creation of a Single Patient Record (SPR) is one of the most significant reforms to health data in a generation.

Views & Analysis

Elon Musk, pharma, and the future of Twitter

Musk’s arrival at the social platform has raised questions for users, which includes pharma companies who use Twitter for marketing and patients who utilise it to engage with their medical

Patients

Endometriosis: hidden suffering and disease burden

Improving patient outcomes starts by listening to and understanding their needs.

Views & Analysis

Overcoming the challenges of developing vaccines in an accel...

The COVID-19 pandemic stopped the world in its tracks.

Sales & Marketing

Why trust is becoming pharma’s most important visibility met...

Any gap between an AI-generated answer and a product’s approved profile carries consequences for prescribing decisions and patient safety.

Sales & Marketing

Pharma is marketing to the wrong mind

On the benefits of instinctive marketing, over either rational or emotional.

Digital

Prescribed, but never filled: Why patient access is broken

Patient access is no longer just an administrative backroom function; it is a core determinant of health outcomes.

Digital

Patient access will not improve without better digital found...

Digital health cannot succeed without infrastructure that supports it at every level.

Market Access

Policy in Focus: What’s new with CMS drug price negotiation,...

Hogan Lovells partner Alice Valder Curran returned to elucidate some of the finer points of the latest communication from CMS.

Market Access

Preparing for the pharma fraud enforcement surge

Here is what robust, risk-based compliance looks like in 2026.

Oncology

Establishing ctDNA as a validated primary surrogate endpoint

Circulating tumour DNA (ctDNA) has emerged as a promising primary surrogate endpoint in solid tumour oncology.

Oncology

radiotherapy session for young man with cancer

Early diagnosis means little without timely treatment

Early diagnosis only changes outcomes if it is followed by timely treatment.

Oncology

ASCO 2026: Astellas innovates in ADCs and T Cell engagers, w...

Patients

Why Britain's blood tests are only as reliable as the journe...

What happens in phlebotomy has a huge impact in pathology, and the different funding streams and management means that interests are no longer aligned

Patients